Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2022 | Immune therapy approaches in MDS

Jacqueline Garcia • 28 Sep 2022
SOHO 2022
Myelodysplastic Syndromes Antibodies Azacitidine Magrolimab Sabatolimab

In this video, Jacqueline Garcia, MD, Dana-Farber Cancer Institute, Boston, MA, highlights the importance of novel immune therapy approaches in myelodysplastic syndromes (MDS), and further comments on upcoming clinical trials investigating these approaches. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Jacqueline Garcia

1:29
The current landscape of immunotherapy for AML: an update from ASH 2023
Jacqueline Garcia • 11 Dec 2023
1:23
The current landscape of treatment for HR-MDS: an update from ASH 2023
Jacqueline Garcia • 11 Dec 2023
5:52
Venetoclax in combination with azacitidine for patients with treatment-naïve HR-MDS
Jacqueline Garcia • 11 Dec 2023
5:00
Phase I study of ven/aza maintenance therapy following ven/FluBu2 RIC alloSCT in high-risk MDS/AML
Jacqueline Garcia • 12 Dec 2022

Related Videos

2:22
Haplo-SCT for older patients with AML/MDS, and should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals